囊肿纤维化市场规模、份额、成长分析（按治疗、给药途径、药物类别和地区）- 产业预测（2025 年至 2032 年）

预计 2023 年全球囊肿纤维化市场价值将达到 61 亿美元，到 2032 年将达到 205 亿美元，预测期内（2025-2032 年）的复合年增长率为 13%。

由于患病率上升、治疗方案的进步、新生儿筛检倡议的扩大以及人们对该疾病的认识不断提高，全球囊肿纤维化市场预计将经历显着增长。不断增加的研发力度以及强大的政府支持计画导致囊肿纤维化跨膜传导调节器 (CFTR)调变器激增。透过筛检进行早期发现已显着改善了治疗效果。此外，人们越来越多地转向针对突变的治疗方法，而增加的医疗保健支出和有效的患者权益倡导工作为加强医疗服务提供了新的机会。吸入装置和药物配方的创新正在扩大治疗选择。然而，治疗成本高、患者人数有限、开发时间长以及服务欠缺地区的准入问题等挑战继续影响着市场的发展。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

囊肿纤维化市场规模（依治疗方法及复合年增长率）（2025-2032）

• 市场概览
• 药品
• 装置

囊肿纤维化市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 吸入

囊肿纤维化市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 胰酵素补充剂
• 黏液溶解剂、支气管扩张剂
• 抗生素
• CFTR调变器

囊肿纤维化市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Vertex Pharmaceuticals Incorporated（United States）
• AbbVie Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（United States）
• Chiesi Farmaceutici SpA（Italy）
• Alcresta Therapeutics, Inc.（United States）
• Laurent Pharmaceuticals Inc.（Canada）
• Pulmocide Ltd.（United Kingdom）
• Zambon SpA（Italy）
• Sanofi SA（France）
• Translate Bio（United States）
• Armata Pharmaceuticals, Inc.（United States）

结论和建议

Global Cystic Fibrosis Market size was valued at USD 6.1 Billion in 2023 and is poised to grow from USD 6.7 Billion in 2024 to USD 20.5 Billion by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The global cystic fibrosis market is poised for significant growth driven by rising incidence rates, advancements in therapeutic options, expanded newborn screening initiatives, and heightened awareness of the disease. Increased research and development efforts have led to a surge in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, alongside robust government support programs. Early detection through screening has notably improved treatment efficacy. Additionally, a shift towards mutation-specific therapies is gaining traction, while rising healthcare expenditures and effective patient advocacy initiatives present new opportunities for enhanced care delivery. Innovations in inhalation devices and drug formulations are expanding treatment options. However, challenges such as high treatment costs, limited patient populations, lengthy development timelines, and access issues in underdeveloped regions continue to impact market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cystic Fibrosis Market Segments Analysis

The global cystic fibrosis market is segmented by treatment method, route of administration, and drug class. Based on treatment methods, the market is segmented into medication and devices. Based on the route of administration, the market is segmented into oral and inhaled. Based on drug class, the market is segmented into pancreatic enzyme supplements, mucolytic, bronchodilators, antibiotics, and CFTR modulators. Based on region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa.

Driver of the Global Cystic Fibrosis Market

Advancements in genetic research and innovative therapies, particularly CFTR modulators, are significantly enhancing the health and longevity of individuals affected by cystic fibrosis. These modern treatments uniquely address the fundamental biological underpinnings of the disease rather than merely alleviating its symptoms or associated complications. This targeted approach not only promises better health outcomes but also fosters greater acceptance and integration of these therapies within healthcare systems globally. As the medical landscape evolves, the emphasis on treating the root cause of cystic fibrosis is set to propel increased demand for these transformative treatments, ultimately benefiting patients worldwide.

Restraints in the Global Cystic Fibrosis Market

The global market for cystic fibrosis is significantly hindered by the high costs associated with advanced therapies, particularly CFTR modulators, which are often prohibitive for patients. Many insurance providers show reluctance to offer coverage or reimbursements for these treatments, leading to limited access. This issue is particularly acute in low- and middle-income countries, where the lack of financial support contributes to substantially lower treatment rates. Consequently, these barriers to access stifle overall growth in the cystic fibrosis market, creating disparities in treatment availability and outcomes for patients across different regions.

Market Trends of the Global Cystic Fibrosis Market

The global cystic fibrosis market is witnessing significant transformation driven by advancements in gene editing technologies and innovative CFTR modulators. These emerging therapies target the root genetic causes of the disease, marking a shift from traditional treatment methods. Increased investments in research and development are fostering a wave of mutation-specific approaches, enabling tailored treatment options that cater to individual patient needs. This trend emphasizes a move towards long-term, personalized management strategies, enhancing patient outcomes and quality of life. As new therapeutic modalities continue to evolve, the market is poised for substantial growth and expansion, attracting interest from various stakeholders across the healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Cystic Fibrosis Market Size by Treatment Method & CAGR (2025-2032)

• Market Overview
• Medication
• Devices

Global Cystic Fibrosis Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Inhaled

Global Cystic Fibrosis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Pancreatic Enzyme Supplements
• Mucolytic, Bronchodilators
• Antibiotics
• CFTR Modulators

Global Cystic Fibrosis Market Size & CAGR (2025-2032)

• North America (Treatment Method, Route of Administration, Drug Class)
  • US
  • Canada
• Europe (Treatment Method, Route of Administration, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Method, Route of Administration, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Method, Route of Administration, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Method, Route of Administration, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Vertex Pharmaceuticals Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcresta Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laurent Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pulmocide Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Translate Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Armata Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations